List of Excipients in Branded Drug PRAMOSONE

Generic Drugs Containing PRAMOSONE

Company	Ingredient	NDC	Excipient
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-726	CETYL ALCOHOL
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-726	DIISOPROPYL ADIPATE
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-726	DIMETHICONE

What are the Most Frequently-Used Excipients in PRAMOSONE?

# Of NDCs	Excipient
4	CETYL ALCOHOL
4	DIISOPROPYL ADIPATE
4	DIMETHICONE

PRAMOSONE Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Pramosone is a topical prescription product combining pramoxine hydrochloride, a local anesthetic, with hydrocortisone acetate, a low-potency corticosteroid. Its commercial position depends more on formulation performance, sensory attributes, packaging, and channel execution than on active-ingredient exclusivity. The strongest opportunities are differentiated emulsion systems, preservative optimization, low-irritancy vehicles, pediatric-friendly products, and over-the-counter-style symptom relief under an appropriate regulatory pathway.

What is Pramosone and which drug products compete with it?

Pramosone products are topical combinations intended to reduce itching while treating associated inflammatory skin conditions. U.S. products have been marketed in cream and lotion presentations, generally combining pramoxine hydrochloride at 1% with hydrocortisone acetate at either 1% or 2.5%, depending on the presentation and product configuration.

Attribute	Pramosone commercial profile
Active anesthetic	Pramoxine hydrochloride
Typical concentration	1%
Active anti-inflammatory	Hydrocortisone acetate
Typical concentration range	1% to 2.5%
Dosage forms	Cream and lotion presentations
Primary use	Temporary relief of itching and inflammation
Prescription status	Prescription topical product in the U.S.
Main competitors	Hydrocortisone creams, pramoxine-only products, diphenhydramine topicals, lidocaine products, barrier creams, prescription corticosteroids
Core differentiation	Combined antipruritic and anti-inflammatory action

The product competes against brands such as Sarna, CeraVe Itch Relief, Aveeno Anti-Itch, Cortizone-10, Gold Bond anti-itch products, lidocaine creams, and prescription corticosteroid products. Most competing products do not combine pramoxine with hydrocortisone in the same dosage form.

What excipients are most important in Pramosone formulations?

The excipient system must preserve drug stability, support uniform dosing, limit irritation, and deliver acceptable skin feel. A conventional cream or lotion can perform adequately, but meaningful commercial differentiation requires control of drug release, residue, spreadability, and packaging compatibility.

Cream excipient platform

A Pramosone cream can use a conventional oil-in-water emulsion containing:

• Purified water as the continuous phase
• Fatty alcohols such as cetyl alcohol or stearyl alcohol for structure
• Glyceryl stearate as an emulsifier and consistency agent
• Mineral oil or other emollient hydrocarbons
• Isopropyl myristate or a comparable spreading agent
• Polysorbate and sorbitan ester combinations for emulsion stability
• Propylene glycol or glycerin as humectants and cosolvents
• A preservative system where required
• pH adjusters to maintain skin compatibility and product stability

A cream provides a stronger barrier and more substantive skin feel than a lotion. It is suitable for localized lesions, dry skin, and night use. Its commercial weakness is potential greasiness, slower absorption, and poor acceptance on hairy or large body areas.

Lotion excipient platform

A lotion can reduce residue and improve application over larger areas. Useful excipient classes include:

• Carbomer or acrylate rheology modifiers
• Glycerin and propylene glycol
• Lightweight emollients
• Fatty alcohols
• Nonionic emulsifiers
• Sodium hydroxide or other neutralizers
• Preservatives compatible with the emulsion and packaging system

A lotion has a stronger commercial position for body-wide itching, larger affected areas, and daytime use. The primary technical risk is inadequate suspension or distribution of hydrocortisone acetate, which has limited water solubility.

Ointment platform

An ointment could provide superior occlusion and longer residence time, particularly for very dry, lichenified, or fissured skin. Petrolatum, mineral oil, and wax systems are technically simple and often preservative-light.

The limitation is patient acceptability. Ointments are greasy, can stain clothing, and are less attractive for facial, intertriginous, or daytime use. An ointment would likely complement rather than replace the existing cream and lotion products.

How should formulators manage pramoxine and hydrocortisone compatibility?

Pramoxine hydrochloride is water-soluble, while hydrocortisone acetate is poorly water-soluble. This creates a two-phase formulation problem:

1. Pramoxine must remain uniformly distributed in the aqueous phase.
2. Hydrocortisone acetate must remain finely dispersed or appropriately solubilized.
3. The emulsion must prevent localized concentration gradients during storage and use.
4. The pH must support tolerability without destabilizing the preservative or emulsion system.

The formulation should control particle size for hydrocortisone acetate and confirm content uniformity at the beginning, middle, and end of product life. Developers should also evaluate whether cosolvents such as propylene glycol increase hydrocortisone acetate solubilization without increasing irritation.

A high level of propylene glycol may improve drug delivery but can cause stinging in compromised skin. Glycerin generally improves moisturization and tolerability but can create tackiness. Isopropyl myristate improves spreadability and can reduce drag, but excessive use may increase irritation or alter drug partitioning.

What excipient strategies can create commercial differentiation?

Low-irritancy preservative systems

Preservatives are a major opportunity because patients with eczema, dermatitis, hemorrhoids, or compromised barriers may be sensitive to conventional systems. Candidate approaches include:

• Phenoxyethanol-based systems
• Paraben systems where market acceptance permits
• Organic-acid systems at suitable pH
• Preservative-reduced or preservative-free packaging
• Airless pumps and single-dose packs

Preservative selection must be evaluated against the final pH, emulsion structure, microbial challenge performance, and container closure. A preservative-free product could command a premium if supported by packaging that prevents repeated microbial ingress.

Fragrance-free and dye-free positioning

Fragrance and colorants offer little therapeutic value and can reduce acceptance in sensitive-skin segments. A fragrance-free, dye-free formulation with a low-residue finish would have a clear commercial message for eczema-prone users and pediatric caregivers.

Barrier-supporting excipients

Ceramides, cholesterol, fatty acids, colloidal oatmeal, dimethicone, and petrolatum can improve the product’s position in barrier-impaired skin. The principal issue is regulatory and marketing discipline. Adding a barrier-supporting ingredient can complicate formulation, stability, labeling, and claims if the product is positioned as more than an antipruritic and corticosteroid combination.

Fast-drying lotion systems

A light lotion using volatile or rapidly absorbed emollients could target daytime use and large surface areas. The formulation must avoid excessive alcohol or other solvents that could sting damaged skin. The product should be assessed for rub-in time, whitening, pilling, and transfer to clothing.

Foam and spray presentations

A foam or spray could provide differentiated delivery for scalp, hairy skin, perianal areas, or large lesions. These dosage forms introduce substantial development requirements:

• Propellant or pump compatibility
• Aerosol valve performance
• Flammability assessment
• Dose uniformity
• Container corrosion and extractables
• Dermal deposition and evaporation behavior

A foam product could command higher pricing, but it would require a more complex manufacturing and regulatory package than a conventional cream or lotion.

What patent opportunities exist for Pramosone excipients and formulations?

The active ingredients are old and are unlikely to support meaningful new-molecule exclusivity. Commercial protection would instead depend on formulation, manufacturing, packaging, or use claims.

Potential patentable subject matter includes:

Opportunity	Potential claim focus	Commercial value
Stable emulsion	Defined phase ratio, particle size, pH, viscosity, and preservative system	Moderate
Low-irritancy product	Reduced propylene glycol, fragrance-free system, preservative selection	Moderate
Enhanced delivery	Controlled hydrocortisone acetate deposition or pramoxine release	High if clinically meaningful
Foam or spray	Device, valve, propellant, and dose-delivery combination	High
Packaging	Airless pump, unit-dose tube, or contamination-resistant closure	Moderate
Manufacturing process	Order of addition, homogenization, particle-size control	Moderate
Barrier-supporting formulation	Combination of active ingredients with ceramides, dimethicone, or colloidal oatmeal	Moderate
Pediatric formulation	Low-sting, low-residue, preservative-controlled vehicle	Commercially attractive

A formulation patent must show more than routine excipient substitution. Stronger claims would tie the excipient system to measurable technical results such as improved stability, lower irritation, better dose uniformity, improved skin deposition, or reduced microbial contamination.

What is the FDA regulatory pathway for a new Pramosone formulation?

A directly substitutable generic cream or lotion would generally be evaluated through the abbreviated new drug application pathway if the reference product, dosage form, strength, route, and performance characteristics align with FDA requirements. Excipients do not need to be identical in every case, but the applicant must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA product-specific requirements.

A materially different dosage form, such as foam, spray, gel, or a product with a new clinical claim, may require a 505(b)(2) application. This pathway could support reliance on existing safety and efficacy information while permitting a differentiated formulation.

Key regulatory workstreams include:

• Active-ingredient identity and assay
• Content uniformity
• Microbial limits and preservative effectiveness
• In vitro release testing
• Rheology and viscosity
• Particle-size distribution for hydrocortisone acetate
• Stability under long-term and accelerated conditions
• Container-closure integrity
• Dermal irritation and sensitization
• Comparative clinical or pharmacokinetic data where required

The FDA Inactive Ingredient Database can support excipient precedent analysis, but prior use in another topical product does not eliminate the need to justify concentration, route, dosage form, and patient population.

When does Pramosone lose exclusivity and what is the generic-entry risk?

Pramosone’s principal commercial vulnerability comes from the age of its active ingredients and the availability of alternative topical antipruritic and corticosteroid products. Generic-entry risk is therefore driven less by active-ingredient patents than by:

• The availability of an approved reference product
• FDA requirements for topical bioequivalence
• Complexity of the cream or lotion vehicle
• Difficulty reproducing hydrocortisone acetate distribution
• Formulation-specific patents
• Product-specific litigation
• Manufacturing scale and supply reliability

A Paragraph IV challenge would be relevant only if an applicant certifies against listed patents for the reference product. The practical barrier may be formulation sameness and topical bioequivalence rather than patent duration. Orange Book patent listings and exclusivity data should be reviewed for the applicable Pramosone NDA and presentation before making a launch decision. Older topical products may have limited or no strategically important listed patents.

Which companies could challenge or compete with Pramosone?

The competitive field includes four groups:

1. Generic dermatology manufacturers producing hydrocortisone, pramoxine, or combination products.
2. Consumer-health companies selling OTC antipruritic creams and lotions.
3. Specialty dermatology companies developing foams, sprays, and low-irritancy vehicles.
4. Contract manufacturers with semi-solid topical capabilities.

Companies with established topical platforms have advantages in scale, tube filling, emulsification, preservative testing, and pharmacy distribution. Consumer-health companies have stronger retail access and may compete through packaging, price, and brand recognition rather than prescription-channel differentiation.

What commercial opportunities have the strongest return profile?

Prescription generic cream or lotion

This is the lowest-risk opportunity but also the most exposed to price competition. The best target is a formulation with reliable content uniformity, stable supply, and a clear substitution position.

Premium fragrance-free lotion

A light, non-greasy lotion could target patients who reject conventional creams. Commercial differentiation would depend on sensory testing and prescriber adoption.

Pediatric and sensitive-skin product

A low-sting, fragrance-free, dye-free formulation with a carefully selected preservative system could address a high-value segment. Labeling and corticosteroid-use restrictions would require disciplined positioning.

Foam or spray

This is the highest-differentiation opportunity. It may support stronger pricing and a 505(b)(2) strategy, particularly for hairy areas, scalp use, and large treatment surfaces.

Barrier-supporting combination

Adding ceramides, dimethicone, or colloidal oatmeal could expand use among patients with dry, irritated skin. The commercial value depends on avoiding claims that trigger a more demanding regulatory classification.

How strong is the Pramosone formulation opportunity?

The opportunity is moderate for a conventional generic and stronger for a differentiated delivery system. A simple cream is vulnerable to substitution and price erosion. A technically distinctive lotion, foam, spray, or preservative-controlled product has greater potential for product-level differentiation and formulation patent protection.

The strongest development package would combine:

• Pramoxine hydrochloride 1% and hydrocortisone acetate at the intended labeled strength
• Fragrance-free and dye-free composition
• Low-irritancy preservative strategy
• Controlled hydrocortisone acetate particle size
• Fast rub-in and low residue
• Airless or contamination-resistant packaging
• Comparative in vitro release and skin-deposition data
• A patent claim directed to the complete formulation and manufacturing process

Key Takeaways

• Pramosone is a pramoxine hydrochloride and hydrocortisone acetate topical combination.
• The active ingredients are old; commercial protection is primarily formulation-led.
• Creams and lotions remain the lowest-risk development targets.
• Foam, spray, airless-packaged lotion, and preservative-controlled products offer stronger differentiation.
• Hydrocortisone acetate suspension uniformity is a central technical risk.
• Excessive propylene glycol, alcohol, or preservative loading may increase irritation.
• A 505(b)(2) strategy may be relevant for a materially different dosage form.
• Conventional generic entry is likely to face formulation and topical bioequivalence requirements more than fundamental molecule-patent barriers.
• The most attractive commercial segment is a low-irritancy, fragrance-free, low-residue product for sensitive or barrier-impaired skin.

FAQs

Can Pramosone be reformulated as a preservative-free cream?

Yes. A preservative-free cream would require a validated microbial-control strategy based on packaging, manufacturing controls, water activity, and container-closure integrity. An airless pump or unit-dose package would be more defensible than a conventional multi-use jar.

Is a Pramosone foam likely to be patentable?

A foam may support patent claims if it has a non-obvious excipient system, improved drug deposition, superior stability, or a distinctive delivery device. A simple conversion of a known cream into foam form would face a weaker patent position.

Which excipient creates the greatest formulation risk?

The greatest risk usually comes from balancing hydrocortisone acetate dispersion with acceptable skin feel and irritation. Propylene glycol, surfactant load, preservative concentration, and particle-size control require joint optimization.

Could a Pramosone product be sold over the counter?

A new OTC product would require an appropriate FDA monograph pathway or an approved NDA. The presence of pramoxine and hydrocortisone does not by itself establish OTC eligibility for a specific combination, strength, claim set, or dosage form.

Are barrier ingredients commercially useful in Pramosone?

Yes. Ceramides, dimethicone, petrolatum, and colloidal oatmeal can improve moisturization and consumer positioning. Their inclusion must be supported by compatibility, stability, preservative, labeling, and claim analyses.

References

1. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (1999). Guidance for industry: Topical dermatologic drug product NDAs and ANDAs: In vivo bioavailability, bioequivalence, in vitro release, and associated studies. https://www.fda.gov/
4. U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development. https://www.fda.gov/
5. DailyMed. (2024). Pramoxine hydrochloride and hydrocortisone acetate topical products. National Library of Medicine. https://dailymed.nlm.nih.gov/